CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2021. The put-call ratio across all filers is 1.14 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $38,588,052 | -17.6% | 849,938 | +1.8% | 0.01% | -16.7% |
| Q2 2023 | $46,854,873 | +27.9% | 834,607 | +3.0% | 0.01% | +20.0% |
| Q1 2023 | $36,635,608 | +114115.0% | 809,984 | +2.6% | 0.01% | 0.0% |
| Q4 2022 | $32,076 | -99.9% | 789,098 | +3.2% | 0.01% | -37.5% |
| Q3 2022 | $49,971,000 | +15.1% | 764,676 | +7.1% | 0.01% | +33.3% |
| Q2 2022 | $43,401,000 | +4.3% | 714,195 | +7.7% | 0.01% | +20.0% |
| Q1 2022 | $41,622,000 | +729.0% | 663,089 | +900.6% | 0.01% | +400.0% |
| Q4 2021 | $5,021,000 | -30.4% | 66,266 | +2.8% | 0.00% | 0.0% |
| Q3 2021 | $7,214,000 | -30.2% | 64,455 | +0.9% | 0.00% | 0.0% |
| Q2 2021 | $10,337,000 | +32.5% | 63,855 | -0.3% | 0.00% | 0.0% |
| Q1 2021 | $7,802,000 | -2.9% | 64,036 | +22.0% | 0.00% | 0.0% |
| Q4 2020 | $8,038,000 | +87.6% | 52,500 | +2.5% | 0.00% | 0.0% |
| Q3 2020 | $4,285,000 | +23.0% | 51,238 | +8.1% | 0.00% | 0.0% |
| Q2 2020 | $3,483,000 | +91.3% | 47,399 | +10.4% | 0.00% | – |
| Q1 2020 | $1,821,000 | -61.9% | 42,950 | -45.3% | 0.00% | – |
| Q4 2019 | $4,778,000 | +203.0% | 78,468 | +103.9% | 0.00% | – |
| Q3 2019 | $1,577,000 | -13.4% | 38,476 | -0.6% | 0.00% | – |
| Q2 2019 | $1,822,000 | +32.2% | 38,700 | +0.3% | 0.00% | – |
| Q1 2019 | $1,378,000 | -31.0% | 38,588 | -44.8% | 0.00% | – |
| Q4 2018 | $1,998,000 | +25.8% | 69,946 | +95.2% | 0.00% | – |
| Q3 2018 | $1,588,000 | -23.8% | 35,825 | +0.9% | 0.00% | -100.0% |
| Q2 2018 | $2,085,000 | +65.9% | 35,495 | +29.0% | 0.00% | – |
| Q1 2018 | $1,257,000 | +98.6% | 27,513 | +1.9% | 0.00% | – |
| Q4 2017 | $633,000 | +34.1% | 26,988 | +2.2% | 0.00% | – |
| Q3 2017 | $472,000 | +60.5% | 26,418 | +43.7% | 0.00% | – |
| Q2 2017 | $294,000 | -35.9% | 18,386 | -12.9% | 0.00% | – |
| Q1 2017 | $459,000 | +23.7% | 21,110 | +15.0% | 0.00% | – |
| Q4 2016 | $371,000 | – | 18,350 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |